asa glp 1 statement glp-1 A narrative review of glucagon-like peptide-1 receptor agonists prior to deep sedation or general anesthesia Perioperative management of patients taking

Are they getting broken down

Suggested improvements and supplements to guidelines Point-of-care ultrasound (POCUS) has become the de facto option for many centers around the world when assessing patients on GLP-1 RAs before procedures, and many articles assessed in this study have indicated the use of POCUS or other gastric imaging, such as nuclear scintigraphy or gastric motility breath test, in the perioperative setting (Oprea et al

Logging meals when appetite is low needs to be effortless

John-Michael Gamble, PhD, Clinical Associate Professor at the University of Waterloo, Canada, discussed the origin and biological plausibility of the concern over suicide risk in people using GLP-1 receptor agonists, relevant scientific evidence and its limitations, and the implications for prescribers and their patients

The pathways with the strongest human-relevant evidence are the peripheral anti-inflammatory effects (reduction in systemic hs-CRP and cytokines) and the systemic metabolic improvements (glycemic control, weight reduction), both of which are well-documented in clinical data

Structural insights into the activation of GLP-1R by a small molecule agonist